Nasdaq · Healthcare
NOVAVAX INC (NVAX)
As-reported financials and recent SEC filings for NOVAVAX INC, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$1.12B
Net income
$440.3M
Net margin
39.2%
Diluted EPS
$2.58
ROE
-344.7%
P/E (TTM)
3.4×
Market cap
$1.46B
Debt / equity
-1.9×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $1.12B | $682.2M | $983.7M | $1.98B | $1.15B |
| Gross profit | — | $479.4M | $639.9M | $1.08B | — |
| Operating income | $452.8M | $-248.9M | $-566.5M | $-644.7M | $-1.69B |
| Net income | $440.3M | $-187.5M | $-545.1M | $-657.9M | $-1.74B |
| Diluted EPS | $2.58 | $-1.23 | $-5.41 | $-8.42 | $-23.44 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-23
View on EDGAR →42026-06-23
View on EDGAR →42026-06-23
View on EDGAR →42026-06-23
View on EDGAR →42026-06-23
View on EDGAR →42026-06-23
View on EDGAR →42026-06-23
View on EDGAR →42026-06-23
View on EDGAR →Go deeper on NVAX
Search NOVAVAX INC’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.